Pandemic Timeline

Sequoia Pharmaceuticals files patent US7151163: Antiviral agents for the treatment, control and prevention of infections by coronaviruses

The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.

— Patent US7151163B2

From the Reiner/Martin interview:

Dr David Martin  25:57

The patent in question, the April 28th 2003 patent 7151163, issued to Sequoia Pharmaceuticals has another problem. The problem is it was issued and published before the CDC patent on Coronavirus was actually allowed. So the degree to which the information could have been known by any means other than insider information between those parties is zero. It is not physically possible for you to patent a thing that treats a thing that had not been published, because CDC had paid to keep it secret. This, my friends is the definition of criminal conspiracy racketeering and collusion. This is not a theory. This is evidence. You cannot have information in the future in form [for] a treatment for a thing that did not exist.

Reiner Fuellmich  27:16

This could well blow up into a Rico case, ultimately.

Dr David Martin  27:20

This is, it is a Rico case. It’s not could blow up into it, it is a Rico case. And the Rico pattern, which was established in April of 2003 for the first Coronavirus, was played out to exactly the same schedule when we see SARS CoV 2 show up when we have Moderna getting the spike protein sequence by phone from the vaccine research centre at NIAID prior to the definition of the novel subclade. How do you treat a thing before you actually have the thing?

Reiner Fuellmich Interviews Dr David Martin

Sources:

Related:

See also, on this site:

 

 

 

Comments are closed.